|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>CYP2C19*2</i> and <i>CYP2C19*17</i> carrier status correlates with PR in ACS patients treated with clopidogrel and thus might be useful for pre-selecting patients who will and who may not be suitable for PGDE of anti-platelet treatment.
|
30103241 |
2018 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2C19*2 allele and HPR by ADP are both independently associated with an increased risk of MACE in the first 6 months after ACS.
|
22390861 |
2012 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
CYP2C19 metabolizer status and GRACE score are readily available predictive approaches for MACEs, and their combination derives a more accurate long-term MACE prediction in clopidogrel-treated patients with ACS undergoing PCI.
|
30193195 |
2018 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2C19 and PON1 Q192R variants influence ADP-induced platelet inhibition by thrombelastography (TEG) in ACS patients with clopidogrel.
|
31772608 |
2019 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A recent clinical trial has demonstrated that patients with acute coronary syndromes (ACS) and the reduced function allele CYP2C19*2 (*2 allele), who are treated with thienopyridines, have an increased risk of adverse cardiac events with clopidogrel, but not with prasugrel.
|
22974536 |
2012 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
About three quarters of Japanese patients with ACS carried CYP2C19 variant alleles.
|
23886632 |
2013 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although limited prospective trial data are available to support the utility of routine CYP2C19 testing, the increased risks for reduced clopidogrel efficacy among ACS/PCI patients that carry CYP2C19 loss-of-function alleles should be considered when genotype results are available.
|
26173871 |
2015 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BACKGROUND The aim of this study was to observe the effects of genetic polymorphism of CYP2C19 on inhibitory effects of ticagrelor (Tic) and clopidogrel (Clo) towards post-percutaneous coronary intervention (PCI) platelet aggregation (IPA) and major cardiovascular events (MACE) in patients with acute coronary syndromes (ACS).
|
27977637 |
2016 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Compared to clopidogrel, prasugrel produced a stable platelet aggregation inhibitory effect in patients with ACS regardless of CYP2C19 genotype, reduced cardiac enzyme release, and prevented cardiac remodeling after ACS.
|
30983087 |
2020 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
|
26521100 |
2016 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic CYP2C19 polymorphisms are relative to the inferior, the antiplatelet activity after clopidogrel admission and may increase the incidence of ischemic events in patients with ACS.
|
26265611 |
2015 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genotyping of CYP2C19 and MACE of 934 ACS patients with PCI on clopidogrel maintenance therapy were analyzed.
|
29243114 |
2018 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here we evaluated the clinical outcomes of DAPT guided by CYP2C19 polymorphisms after implantation of second-generation drug-eluting stents (DESs) for ACS management.
|
29279531 |
2018 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Homozygosity (A/A) for CYP2C19*2 mutant is an independent determinant of prognosis in patients with ACS.
|
21778720 |
2011 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Interaction between platelet-derived microRNAs and CYP2C19*2 genotype on clopidogrel antiplatelet responsiveness in patients with ACS.
|
28734158 |
2017 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our aim was to demonstrate that the sequential use of the Verigene® rapid CYP2C19 test for genetic profiling and the VerifyNowTM bedside test for platelet function measurement in ACS patients may optimise P2Y12 inhibition.
|
26423110 |
2016 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients hospitalized for ACS were randomly assigned to standard of care or the pharmacogenomic arm, which included the genotyping of ABCB1, CYP2C19*2, and CYP2C19*17 using an ST Q3 system that provides data within 70 min at each patient's bedside.
|
29540324 |
2018 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with poor and intermediate CYP2C19 metabolizers treated with clopidogrel incur higher cardiovascular event rates, including myocardial infarction, stroke, and stent thrombosis, following ACS than patients with normal CYP2C19 function.
|
26108379 |
2015 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Presence of specific CYP2C19 allele significantly influences clopidogrel metabolism and associated outcomes in patients with ACS.
|
31498157 |
2019 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Seven studies including cost-effectiveness and risk-benefit analyses of CYP2C19 genotype-guided antiplatelet therapy in ACS patients were reviewed.
|
25660101 |
2015 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Seventy-six patients (median age 63, range 37-91 years) with an ACS who underwent PCI were screened for <i>CYP2C19</i> and <i>ABCB1</i> gene polymorphisms with real-time polymerase chain reaction: <i>CYP2C19*2</i>, <i>CYP2C19*17</i>, and <i>ABCB1 3435</i>.
|
29075133 |
2017 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Six strategies for selection of P2Y<sub>12</sub> inhibitors in ACS were compared from the US healthcare system perspective: (1) clopidogrel for all (universal clopidogrel); (2) ticagrelor guided by platelet reactivity assay (PRA; clopidogrel + phenotype); (3) ticagrelor use only in CYP2C19 poor metabolizers (genotype + conservative ticagrelor); (4) ticagrelor use in both CYP2C19 intermediate and poor metabolizers (genotype + liberal ticagrelor); (5) ticagrelor use only in patients with CYP2C19 polymorphisms and clopidogrel nonresponse by PRA (genotype + phenotype); and (6) ticagrelor for all (universal ticagrelor).
|
31367811 |
2019 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The CYP2C19 genotype is a predictor of adverse cardiovascular events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) treated with clopidogrel.
|
23137413 |
2013 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The CYP2C19 G681A polymorphism and omeprazole use were both known for retarding the effects of clopidogrel under broad cardiovascular conditions; however, data from ACS patients were limited.
|
31658140 |
2019 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this pilot prospective study was to evaluate 12-month cardiovascular outcomes in elderly patients with acute coronary syndrome (ACS) receiving dual antiplatelet therapy (aspirin and clopidogrel) according to the clustering of CYP2C19 and ABCB1 genetic variants.
|
29936693 |
2018 |